Dystrophin alterations in the brain have been associated with an increased risk of epilepsy in Becker and Duchenne muscular dystrophies (BMD and DMD). Moreover, an association between the mutation site and the risk of epilepsy is not ruled out. The aim of this systematic review and meta-analysis was to estimate the prevalence of epilepsy in BMD and DMD populations and to establish a possible association between the site of mutation in the dystrophin gene and the risk of epilepsy. Systematic searches of Medline, Scopus, Web of Science, and Cochrane Library were conducted to identify relevant studies published from inception to January 2022. Observational studies of participants with BMD/DMD estimating the prevalence of epilepsy were included. The main outcome was the prevalence of epilepsy, and the secondary outcome was the prevalence ratio considering genotype. A random effects meta-analysis was performed for the prevalence of epilepsy. Eight studies were included in the systematic review and meta-analysis. The prevalence of epilepsy was 7% (95% CI 3-11%) in BMD, 5% (95% CI 2-8%) in DMD, and 5% (95% CI 3-7%) in the overall estimate. No association was observed between mutation site and the prevalence of epilepsy. BMD/DMD is strongly associated with the prevalence of epilepsy, with a higher prevalence in BMD/DMD populations than in the general population, probably owing to alterations in Dp427. The current evidence does not support the hypothesis that Dp140 or Dp71 affect epilepsy risk.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00415-022-11040-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Building a growing genomic repository for maternal and fetal health through the PING Consortium.
Pediatr Res
January 2025
Center for Genetic Medicine, Children's National Research Institute, Washington, DC, USA.
Background: Prenatally transmitted viruses can cause severe damage to the developing brain. There is unexplained variability in prenatal brain injury and postnatal neurodevelopmental outcomes, suggesting disease modifiers. Of note, prenatal Zika infection can cause a spectrum of neurodevelopmental disorders, including congenital Zika syndrome.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
NYU Grossman School of Medicine, New York, NY, USA.
Background: Prevalence of epilepsy is increased among Alzheimer's Disease (AD) patients and cognitive impairment is common among people with epilepsy, with seizures occurring in 10-22% of AD patients, subclinical epileptiform abnormalities in 22-54% of AD patients, and cognitive deficits in up to 80% of epilepsy patients. These shared pathophysiological changes remain poorly defined.
Methods: We aimed to identify protein differences associated with epilepsy and AD using published proteomics datasets, including our previous analysis in epilepsy hippocampus and from our searchable database of 38 AD proteomics studies (NeuroPro).
Background: Neuropsychiatric disorders including depression, insomnia, epilepsy, schizophrenia, and attention-deficit and hyperactivity disorder (ADHD) have been associated with a neurodegenerative process and linked to increased risk for Alzheimer's Disease (AD). Because of the shared biological mechanisms of AD and neuropsychiatric disorders, we hypothesized that pharmacologic treatment for neuropsychiatric disorders could impact the risk for AD. CNS drugs that are first-line therapies for neuropsychiatric disorders (including antidepressants, sedatives, anticonvulsants, antipsychotics, and stimulants) were investigated for impact on AD incidence.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
Department of Neurology, National Neuroscience Institute, Singapore, Singapore, Singapore, Singapore.
Background: Epilepsy is associated with increased risk for dementia, which adversely impacts the quality of life for patients and their families. Mild cognitive impairment (MCI) is the prodromal stage of dementia offering an important window for intervention. However, the epilepsy related risk factors for MCI are not well understood.
View Article and Find Full Text PDFExogenous ketone bodies and the ketogenic diet as a treatment option for neurodevelopmental disorders.
Front Nutr
December 2024
Health Via Modern Nutrition Inc. (H.V.M.N.), San Francisco, CA, United States.
Background: Despite being the most prevalent neurodevelopmental disorders, there are comparatively few treatment options available to patients presenting with autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). The ketogenic diet has historically shown therapeutic utility in treating refractory epilepsy, an adjacent neuropsychiatric condition, in children, adolescents and adults. The following review explores preclinical and clinical literature focusing on the therapeutic potential of the ketogenic diet and exogenous ketone body supplementation in treating common neurodevelopmental disorders.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!